MedTrace Logo

CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL)

NCT01804335 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2016-04-13

No results posted yet for this study

Summary

The goal of this clinical research study is to learn if CD5789 is safe and tolerable when given to patients with early stage CTCL.

CD5789 is designed to attach to tumor cells and change their genetic material. This may stop the growth of the tumor cells.

Conditions

Interventions

DRUG

CD5789 0.01% Cream

CD5789 0.01% cream applied on the lesions once daily for twelve weeks.

Sponsors & Collaborators

  • Galderma R&D

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Madeleine Duvic, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01804335 on ClinicalTrials.gov